MECHANISM OF ACTION
Intermediate affinity binding
TheraCIM® binds to EGFR with intermediate affinity (10-8 and 10-9 M) causing high tumour uptake and low uptake in normal tissue. This results in effective EGFR blockade without causing deleterious effects on the skin, because the optimal dose is far lower than the toxic dose.
Anti Cancer properties of TheraCIM®:
Mediates complement-dependent cytotoxicity (CDC) and antibody-dependent cellular cytotoxicity (ADCC) activity
Learn about the proposed mechanism of TheraCIM®